Thursday, January 12, 2017 11:38:27 AM
- PD said they plan to monetize TRACE technology this year
- PD said they will be announcing collaborations for TRACE via the TAP shortly
- On track to commence patient enrollment for registration trial in Q2 2017
- Plan is to move ahead with the registration trial with a multinational
- Exit opportunity may present itself within the next 18 months for lead program (EP IL-12 + anti-PD1)
- I understood the above statement as they will retain TRACE tech, and opportunities to partner it out beyond anti-PD1 candidates in the event of a sale of the lead candidate; PD talks about keeping a piece of the pie
Audio from the webcast to verify the above (30 mins):
https://event.webcasts.com/viewer/event.jsp?ei=1130360
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM